🇺🇸 FDA
Pipeline program

0.2 mg/kg ketamine

NMCSD.2014.0031

Phase 3 small_molecule terminated

Quick answer

0.2 mg/kg ketamine for Depression is a Phase 3 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Depression
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials